Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds
The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President…
The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President…
Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the…
Chimeric antigen receptor (CAR) T-cell therapies have drastically changed treatment paradigms in relapsed and refractory (R/R) haematological malignancies since the…
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, the development of…
The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and…
On 7 April, at the 2025 American Academy of Neurology (AAN) meeting, a poster presentation by the Peking Union Medical…
Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference…
Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference…
The uveitis market is expected to grow at a compound annual growth rate of 10.9% throughout the forecast period (2023…
Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T,…